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RESEARCH ARTICLE Open Access
Association of different iron deficiency
cutoffs with adverse outcomes in chronic
kidney disease
Michele F. Eisenga1,5* , Ilja M. Nolte2, Peter van der Meer3, Stephan J. L. Bakker1 and Carlo A. J. M. Gaillard1,4
Abstract
Background: Iron deficiency is highly prevalent in chronic kidney disease (CKD) patients. In clinical practice, iron
deficiency is defined based on a combination of two commonly used markers, ferritin and transferrin saturation
(TSAT). However, no consensus has been reached which cutoffs of these parameters should be applied to define
iron deficiency. Hence, we aimed to assess prospectively which cutoffs of ferritin and TSAT performed optimally for
outcomes in CKD patients.
Methods: We meticulously analyzed 975 CKD community dwelling patients of the Prevention of Renal and Vascular
Endstage Disease prospective study based on an estimated glomerular filtration rate < 60 ml/min/1.73m2, albuminuria
> 30 mg/24 h, or albumin-to-creatinine ratio≥ 30 mg/g. Cox proportional hazard regression analyses using different
sets and combinations of cutoffs of ferritin and TSAT were performed to assess prospective associations with all-cause
mortality, cardiovascular mortality, and development of anemia.
Results: Of the included 975 CKD patients (62 ± 12 years, 64% male with an estimated glomerular filtration rate of 77
± 23 ml/min/1.73m2), 173 CKD patients died during a median follow-up of 8.0 (interquartile range 7.5–8.7) years of
which 70 from a cardiovascular cause. Furthermore, 164 CKD patients developed anemia. The highest risk for all-cause
mortality (hazard ratio, 2.83; 95% confidence interval, 1.53–5.24), cardiovascular mortality (4.15; 1.78–9.66), and
developing anemia (3.07; 1.69–5.57) was uniformly observed for a TSAT< 10%, independent of serum ferritin level.
Conclusion: In this study, we have shown that of the traditionally used markers of iron status, reduced TSAT, especially
TSAT< 10%, is most strongly associated with the risk of adverse outcomes in CKD patients irrespective of serum ferritin
level, suggesting that clinicians should focus more on TSAT rather than ferritin in this patient setting. Specific attention
to iron levels below this cutoff seems warranted in CKD patients.
Keywords: Iron deficiency, CKD, Mortality, Cutoffs, Ferritin, TSAT
Background
Iron deficiency (ID) is the most common nutritional de-
ficiency worldwide, affecting up to 25% of the population
[1–3]. A variety of causes are responsible for the deple-
tion of iron stores, ranging from deficient dietary iron
intake to increased blood loss (e.g. gastro-intestinal can-
cers, peptic ulcera) [4, 5]. In addition, in chronic disease
populations, due to the pro-inflammatory state that
chronic diseases constitute, upregulation of serum hepci-
din blocks iron absorption from the gut and iron release
from the reticulo-endothelial system leading to reduced
iron availability despite adequate stores [6]. Indeed, in
these populations, such as chronic heart failure (CHF)
and chronic kidney disease (CKD), it has been shown
that ID is highly prevalent and associated with an in-
creased risk of morbidity and mortality, independent of
potential confounders, including anemia [7–9].
The definition of ID is still a matter of debate [10, 11].
ID is generally divided into absolute ID (low iron stores)
and functional ID (insufficient iron supply to the bone
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marrow despite sufficient iron stores). Due to the existence
of both absolute ID and functional ID and the absence of
an unequivocal gold standard, it remains challenging to
correctly identify ID [12]. Clinicians and epidemiologists
alike predominantly rely on two frequently used markers,
namely ferritin (for iron load) and transferrin saturation
(TSAT, for iron transport availability) [13–15]. However, to
date, no consensus has been reached which cutoffs of these
parameters should be utilized to define absolute and func-
tional ID per population. Except perhaps in the cardiology
field where absolute ID is defined as a ferritin level
< 100 μg/L, and functional ID as a TSAT< 20% accom-
panied by ferritin levels between 100 and 299 μg/L [7, 16].
Currently in nephrology, the Kidney Disease Improving
Global Outcomes (KDIGO) committee recommends a trial
of 1 to 3 months of oral iron therapy in non-dialysis CKD
patients when TSAT levels are below 30% and ferritin
below 500 μg/L. However, it is not known which cutoffs of
ferritin and/or TSAT perform best with respect to predict-
ing anemia, response to iron treatment or outcome [17].
Correctly defining which cutoffs of ferritin and TSAT
associate with outcome would identify which patients
are most at risk to develop these outcomes and thus in
which patients correction of ID could potentially have
the greatest benefit. Therefore, the present study was
performed to define which cutoffs of serum ferritin and
TSAT perform optimally for the risk of all-cause mortal-
ity, cardiovascular mortality, and risk of developing
anemia in CKD patients.
Methods
Study population
Data was used from the Prevention of Renal and Vascular
End-Stage Disease (PREVEND) study, of which details have
been published elsewhere [18]. In brief, from 1997 to 1998,
all inhabitants of the city of Groningen, The Netherlands,
ranging between 28 and 75 years of age, received a ques-
tionnaire to complete regarding demographics, disease his-
tory, smoking status, medication use, and a vial to collect a
first morning urine sample (n = 85,421). Eventually, 40,856
subjects responded on the request (47.8%). We excluded
subjects with type 1 diabetes mellitus (defined as the use of
insulin) and pregnant women. After completion of the
screening protocol, subjects with an urinary albumin excre-
tion (UAE) ≥10 mg/L (n = 6000) and a randomly selected
control group with an UAE < 10 mg/L (n = 2592) formed
the baseline PREVEND cohort (n = 8592). For current ana-
lyses, we used data from the second survey, which oc-
curred between 2001 and 2003 (n = 6894), due to the
availability of iron status parameters at this visit. Partici-
pants visited the outpatient clinic twice and were requested
to collect two consecutive 24-h urine specimens. We ex-
cluded 436 subjects due to missing values for serum fer-
ritin or serum transferrin, resulting in the inclusion of
6458 subjects. For current analyses, we selected all patients
with CKD, based on an eGFR< 60 ml/min/1.73m2 or albu-
minuria > 30 mg/24 h or albumin-to-creatinine ratio ≥
30 mg/g (n = 975, flowchart depicted in Fig. 1). As sensitiv-
ity analyses, we restricted the CKD patients group to pa-
tients with solitarily an eGFR< 60 ml/min/1.73m2 (n =
274). The PREVEND study protocol was approved by the
institutional medical review board and was carried out in
accordance with the Declaration of Helsinki. Written in-
formed consent was obtained from all participants.
Measurements
Fasting blood samples were drawn in the morning from
all participants from 2001 to 2003. All hematologic mea-
surements were measured in fresh venous blood. Ali-
quots of these samples were stored immediately at − 80 °
C until further analysis. Measurements were performed
at the central laboratory of the University Medical Cen-
ter Groningen. Serum creatinine was measured using an
enzymatic, IDMS-traceable method on a Roche Modular
analyzer (Roche Diagnostics, Mannheim, Germany). For
estimating glomerular filtration rate (eGFR), the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
was applied [19]. In the PREVEND study, serum iron
(μmol/L), ferritin (μg/L), and transferrin (g/L) were mea-
sured using a colorimetric assay, immunoassay, and immu-
noturbidimetric assay, respectively (Roche Diagnostics).
Main outcomes
We assessed the association of ferritin and TSAT with
all-cause mortality, cardiovascular mortality and risk of
developing anemia. In the PREVEND cohort, data on
mortality were received through the municipal register.
Cause of death was gathered by combining the number
reported on the death certificate with the primary cause
of death as classified by the Dutch Central Bureau of
Statistics. Anemia was defined as a hemoglobin level
lower than 7.5 mmol/L (12 g/dL) for women, and a
hemoglobin level lower than 8.1 mmol/L (13 g/dL) for
men [20]. Follow-up was performed until the 1st of
January 2011 in the PREVEND study.
Statistical analyses
Baseline variables are described by means with SD when
variables are continuous and normally distributed, by
medians with interquartile range when the distribution
is skewed, or as numbers and corresponding percentages
for categorical data. Differences between groups were
assessed with a Student’s t-test for normally distributed
variables, a Mann-Whitney U-test for skewed variables,
and a Chi-square test for categorical variables. We evalu-
ated the presence of high ferritin levels (suggestive of
iron trapping) despite a functional iron deficiency by cal-
culating the percentage of CKD patients with ferritin
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levels higher than 500 μg/L in combination with a
TSAT< 20%. Cox regression analyses were performed to
investigate the hazard rates of the individual cutoffs of
ferritin and TSAT and all combinations of serum ferritin
(i.e. < 20, < 50, < 100, < 200, < 300, and < 500 μg/L) and
TSAT (i.e. < 10, < 15, < 20, < 25, and < 30%) for the re-
spective outcomes while adjusting for age and sex. Sep-
arately, we also assessed conditional definitions as
defined in the Ferinject Assessment in Patients with Iron
Deficiency and Chronic Heart Failure (FAIR-HF) study,
i.e. ferritin< 100 μg/L or TSAT< 20% with ferritin <
300 μg/L, and in the Ferinject in patients with Iron defi-
ciency anemia and Non-Dialysis-dependent Chronic
Kidney Disease (FIND-CKD) study, i.e. ferritin< 100 μg/
L or TSAT< 20% with ferritin < 200 μg/L [7, 21]. Based
on these two conditional definitions, we extended the
possibilities of conditional definitions with a TSAT lower
than 10% and lower than 15% in combination with a fer-
ritin level < 200 μg/L or < 300 μg/L. To really allow iden-
tification of the group with the highest risk based on
cutoffs, in each analysis the reference group is defined as
the group above the studied cutoff, as a result the refer-
ence group in the Cox regression analyses is variable,
e.g. when the combined definition of TSAT< 20% with
ferritin < 300 μg/L was analyzed, the reference group
was TSAT> 20% with ferritin> 300 μg/L. Cutoffs were
chosen as rounded numbers rather than subdividing
TSAT and ferritin levels in quartiles or quintiles to allow
comparison with cutoffs generally chosen in clinical prac-
tice and research studies. As sensitivity analyses, we per-
formed subanalyses in 274 CKD patients with solitarily an
eGFR lower than 60 ml/min/1.73m2, and in 717 CKD pa-
tients with data available on hs-CRP, as inflammation
marker, and on serum albumin, as proxy for malnutrition.
Finally, we made splines of ferritin and TSAT with
all-cause mortality using restricted cubic splines based on
Cox regression proportional hazard analyses. Data were
analyzed using IBM SPSS software, version 23.0 (SPSS
Inc., Chicago, IL), and R version 3.2.3 (Vienna, Austria).
Results
Patient characteristics
We included 975 CKD patients (62 ± 12 years, 64% male)
with a mean eGFR of 77 ± 23 ml/min/1.73m2. Further
demographics and clinical characteristics of the CKD pa-
tients, dichotomized according to survival status at the end
of the follow-up are shown in Table 1. High ferritin levels
of > 500 μg/L (representing possibly iron overload) in com-
bination with functional iron deficiency (TSAT< 20%) was
present in 6 (0.6%) of the 975 CKD patients.
First, we assessed the impact of using different cutoffs
for ferritin or TSAT as individual markers on the associ-
ation with all-cause mortality. During a median follow-up
of 8.0 (interquartile range 7.5–8.7) years, 173 CKD pa-
tients died. The highest age- and sex-adjusted risk of mor-
tality (HR, 2.83; 95%CI 1.53–5.24) was observed for
Fig. 1 Flowchart of the participants in the study
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TSAT< 10%. Ferritin, as individual continuous marker,
was not associated with increased risk of mortality. When
assessing the impact of using a different combination of
ferritin and TSAT on mortality, the highest risk of mortal-
ity (HR, 2.56; 95%CI 1.35–4.87) was observed for TSAT<
10% in combination with ferritin cutoffs of either < 200,
300, or 500 μg/L (Fig. 2). Full analyses are shown in
Additional file 1. Using a conditional definition did not
improve the observed maximal HR. In restricted cubic
splines, these findings are further illustrated as the same
pattern was observed for continuous variables of ferritin
(Fig. 3a) and TSAT (Fig. 3b).
Second, we assessed the impact of using different
cutoffs for ferritin or TSAT as individual markers on
the association with cardiovascular mortality. Of the
173 deceased CKD patients, 70 were due to cardiovas-
cular cause. The highest risk of cardiovascular mortal-
ity (HR, 4.15; 95%CI 1.78–9.66) was observed for
TSAT< 10%. Ferritin, as individual continuous marker,
was not associated with increased risk of cardiovascu-
lar mortality. When assessing the impact of using a dif-
ferent combination of ferritin and TSAT on mortality,
the highest risk of cardiovascular mortality (HR, 4.17;
95%CI 1.79–9.70) was identified for TSAT< 10% in
Table 1 Baseline characteristics of 975 chronic kidney disease patients


















Age, yr 60 ± 12 63 ± 12 62 ± 11 63 ± 11 59 ± 13 63 ± 11 63 ± 11 64 ± 11
Male sex – no. (%) 17 (42) 151 (54) 277 (67) 180 (74) 59 (35) 136 (62) 317 (70) 113 (84)
Race (n, %) 37 (90) 263 (95) 397 (96) 235 (97) 159 (94) 213 (97) 437 (97) 123 (92)
BMI, kg/m2 27.6 ± 4.8 29.4 ± 5.7 28.3 ± 4.3 27.4 ± 4.1 26.9 ± 5.6 27.9 ± 4.7 28.7 ± 4.6 29.5 ± 4.0
Systolic blood pressure,
mmHg
135 ± 24 140 ± 22 139 ± 22 139 ± 22 133 ± 21 138 ± 21 140 ± 22 145 ± 21
Diabetes Mellitus, n (%) 6 (15) 67 (24) 69 (17) 36 (15) 23 (14) 27 (12) 99 (22) 29 (22)
Current smoking, n (%) 6 (15) 76 (28) 121 (29) 72 (30) 45 (27) 69 (32) 127 (28) 34 (25)
Alcohol use, n(%) 22 (54) 176 (63) 298 (72) 181 (75) 99 (59) 147 (67) 329 (73) 102 (76)
Baseline renal function
Creatinine (μmol/L) 85 (73–113) 90 (79–104) 92 (81–107) 95 (80–106) 85 (74–99) 92 (79–107) 93 (83–108) 93 (84–109)
eGFR (ml/min/1.73m2) 78 ± 26 76 ± 23 78 ± 22 78 ± 22 81 ± 26 76 ± 23 76 ± 22 77 ± 23
CKD stage
Stage I (n, %) 12 (29) 84 (30) 136 (33) 71 (29) 56 (33) 70 (32) 130 (29) 47 (35)
Stage II (n, %) 13 (32) 97 (35) 140 (34) 99 (41) 59 (35) 72 (33) 174 (38) 44 (33)
Stage III (n, %) 10 (24) 76 (27) 114 (28) 60 (25) 37 (22) 62 (28) 126 (28) 35 (26)
Stage IV/V (n, %) 1 (2) 7 (3) 3 (1) 3 (1) 2 (1) 2 (1) 7 (2) 3 (2)
Urinary albumin
excretion (mg/24 h)
51 (36–139) 53 (33–140) 54 (34–111) 56 (36–112) 48 (33–104) 54 (33–107) 57 (34–128) 63 (38–121)
Laboratory parameters
Hemoglobin (g/dL) 12.0 ± 2.1 13.6 ± 1.3 14.2 ± 1.2 14.4 ± 1.0 13.0 ± 0.6 13.9 ± 1.1 14.2 ± 1.2 14.5 ± 1.4
MCV (fL) 82 ± 8 89 ± 5 91 ± 4 92 ± 4 88 ± 7 91 ± 4 91 ± 4 92 ± 6
Ferritin (μg/L) 16 (8–28) 102 (56–175) 132 (72–235) 168 (101–276) 29 (17–40) 74 (62–87) 167 (130–214) 417 (343–553)
TSAT (%) 7 ± 2 16 ± 2 24 ± 3 37 ± 7 18 ± 2 24 ± 2 26 ± 9 29 ± 11
Serum iron (μmol/L) 6 ± 2 11 ± 2 16 ± 3 22 ± 4 13 ± 5 15 ± 5 16 ± 5 17 ± 6
hs-CRP (mg/dL)a 2.7 (1.1–7.9) 4.1 (1.7–7.0) 2.1 (1.1–4.1) 2.0 (1.1–3.9) 2.0 (0.9–5.1) 2.2 (1.2–5.1) 2.6 (1.3–4.7) 2.4 (1.5–4.9)
Albumin (g/L)a 42 ± 2 43 ± 3 43 ± 3 44 ± 3 43 ± 3 43 ± 3 44 ± 3 44 ± 3
Total cholesterol
(mmol/L)
5.1 ± 1.2 5.5 ± 1.2 5.5 ± 1.0 5.5 ± 1.0 5.2 ± 1.2 5.5 ± 1.1 5.5 ± 1.1 5.7 ± 1.2
Glucose (mmol/L) 5.8 ± 2.1 5.9 ± 1.9 5.5 ± 1.5 5.5 ± 1.6 5.4 ± 1.8 5.3 ± 1.3 5.8 ± 1.7 5.9 ± 1.8
Normally distributed variables are shown as mean with standard deviation, whereas skewed variables are shown as medians with interquartile range. aAlbumin
and hs-CRP data were available in 717 patients
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combination with a ferritin cutoff of < 100, 200, 300, or
500 μg/L (Additional file 2).
Third, we examined the impact of using different cutoffs
for ferritin or TSAT as individual markers for the risk of
developing anemia. During median follow-up of 6.2 (2.4–
7.5) years, 164 CKD patients developed anemia. The high-
est risk of developing anemia (HR, 3.07; 95%CI 1.69–5.57)
was observed for TSAT < 10%. Ferritin as individual con-
tinuous marker had the highest risk of anemia with a cut-
off of ferritin< 20 μg/L (HR, 2.95; 95%CI 1.75–4.98). In
the various combinations of ferritin with TSAT, the high-
est risk of developing anemia (HR, 3.07; 95%CI 1.69–5.57)
was identified for TSAT< 10% in combination with a
ferritin cutoff of < 100, 200, 300, or 500 μg/L. All the other
combinations were also positively associated with develop-
ment of anemia albeit less significant (Additional file 3).
As sensitivity analyses, we restricted the group of 975
CKD patients to 274 CKD patients with an eGFR lower
than 60 ml/min/1.73m2. We repeated the analyses of the
different cutoffs of ferritin and/or TSAT with all-cause
mortality, cardiovascular mortality, and risk of anemia.
In these analyses, we identified the same pattern that the
highest risk was particularly observed for a TSAT< 10%
(Additional file 4).
Furthermore, we performed sensitivity analyses in 717
CKD patients of the included 975 CKD patients with
Fig. 2 Hazard ratio of mortality risk by different cutoff values of ferritin and TSAT in chronic kidney disease patients
Fig. 3 Associations of TSAT and ferritin as continuous variables on all-cause mortality in chronic kidney disease patients. Data were fit by a Cox
proportional hazard regression model based on restricted cubic splines. Knots were placed on at 10th, 50th, and 90th percentile of ferritin and
TSAT, respectively. Panel a shows the association between ferritin, adjusted for age and sex, and all-cause mortality. Panel b shows the
association between TSAT, adjusted for age and sex, and all-cause mortality. The black line represents the hazard ratio. The grey area the 95%
confidence interval
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data available on hs-CRP and serum albumin. We re-
peated all the previous analyses on the impact of using
different cutoffs for ferritin and/or TSAT on the associ-
ation with all-cause mortality, cardiovascular mortality,
and risk of anemia. In these analyses, we identified again
the same pattern, i.e. that the highest risk was particu-
larly observed for a TSAT< 10% (Additional file 5).
Discussion
In this study, consisting of a large cohort of CKD pa-
tients, we show the impact of using different cutoffs for
ferritin and/or TSAT on the association with all-cause
mortality, cardiovascular mortality, and the subsequent
development of anemia. Remarkably, in CKD patients
the highest risk to develop adverse outcomes was uni-
formly observed at a low TSAT level, i.e. lower than
10%, largely independent of the level of ferritin. The
current results are of importance for defining ID in CKD
patients and may aid clinicians to focus on these specific
cutoffs for TSAT in order to improve outcome.
To date, there is no consensus in the field of CKD which
cutoffs of ferritin and TSAT should be retained to define
ID. Multiple important studies in CKD patients have uti-
lized different definitions for ID. For example, the
FIND-CKD study used serum ferritin < 100 μg/L or TSAT
< 20% in combination with serum ferritin of < 200 μg/L to
identify patients as iron deficient, whereas Qunibi and col-
leagues defined ID as TSAT ≤25% with ferritin ≤300 μg/L
and Fishbane and colleagues utilized TSAT ≤25% in com-
bination with ferritin ≤200 μg/L to determine ID [21–23].
Currently, the plethora of ID definitions impedes compar-
ability among iron studies. As a result, translation to clin-
ical practice is difficult. Therefore, it is important to
identify optimal cutoffs for CKD patients. Accordingly, in
the present study, we assessed prospectively which cutoffs
for ferritin and TSAT performed optimally for the associ-
ation with adverse outcomes, implicating that, at least in
terms of survival and development of anemia, these se-
lected cutoffs are clinically most relevant.
Previously, few studies have evaluated the accuracy of
serum ferritin and TSAT cutoffs to define ID in CKD pa-
tients in terms of sensitivity and specificity. Fishbane et al.
determined in hemodialysis (HD) patients which levels of
serum ferritin and TSAT were most predictive for ID. The
authors concluded that in erythropoietin-responsive pa-
tients ferritin level of lower than 100 μg/L or TSAT< 18%
are indicative of inadequate iron status, whereas in
erythropoietin-resistant patients a serum ferritin < 300 μg/
L or a TSAT < 27% should be utilized [24]. Also in HD pa-
tients, Kalantar-Zadeh et al. identified high specificity for
a cutoff of serum ferritin < 200 ng/mL and high sensitivity
for a TSAT< 20% [25]. As far as we know, we are the first
in CKD patients to assess the performance of different
cutoffs for ferritin and/or TSAT in terms of prospective
associations with adverse outcomes.
Our results identified TSAT lower than 10% to be the
optimal cutoff associated with increased risk of detri-
mental outcomes in the CKD population. In our popula-
tion of early stage CKD patients, i.e. CKD stadia one to
three, the importance of adequate iron status is evident,
in view of the increased hazard ratios for development
of adverse outcomes. When carefully assessing the haz-
ard ratios for all-cause mortality, cardiovascular mortal-
ity, and risk of anemia, it is clear that the highest risk is
observed for TSAT< 10%, however, also for TSAT< 15%
a significant increased risk in adverse outcomes is ob-
served. It should be noted that the cardiovascular mor-
tality risk associated with ID is markedly higher (nearly
double) than the risk for all-cause mortality. For a cutoff
value of TSAT < 20 and < 30% the observed hazard ratios
for all-cause mortality and cardiovascular mortality are
less impressive, whereas the risk for anemia decreases
steadily with increasing cutoff levels. Conditional defini-
tions as those used previously in the FAIR-HF and
FIND-CKD did not improve the association with in-
creased risk. This suggests that in CKD patients the
main focus should be on low TSAT, especially TSAT
lower than 10%. Based on these results, it may be specu-
lated that failure to correct these low TSAT levels might
jeopardize the survival of CKD patients.
Currently, ferritin and TSAT are the most commonly
used markers in clinical setting to evaluate iron stores and
iron availability. However, there are important drawbacks
on the use of ferritin and TSAT as iron status parameters.
Serum ferritin is an acute-phase reactant and therefore in
chronic disease populations serum ferritin levels will be el-
evated [26, 27]. TSAT also has acute-phase reactivity as
transferrin is elevated in the setting of acute inflammation
which will lower TSAT when circulating iron remains
constant [28]. However, other markers, such as soluble
transferrin receptor, percentage hypochromic red blood
cells, and reticulocyte hemoglobin content, are not readily
available in clinical practice, less well studied, or not used
for other reasons.
Our study has strengths and limitations. Strengths are
that it comprises a large cohort of CKD patients with
availability of data on iron status and that it is the first
study to assess all combinations of cutoffs with respect
to “hard” clinical endpoints. Limitations of the current
study include its observational design, that it comprises
a single center study and that measurement of iron pa-
rameters were performed at a single time point, which
precludes our ability to discern the impact of changes in
iron parameters over time on clinical outcomes. Further-
more, the current study is only valid for early CKD, and
precludes us to discern whether similar results apply for
more advanced CKD stages. Another limitation might be
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that we did not adjust for several potential confounders
in the different associations between ID and outcomes,
however, the primary aim of this study is to study the
prospective associations of ID with adverse outcomes
using several cutoffs for ferritin and TSAT, not to inves-
tigate the mechanisms involved.
Conclusion
In this study, we show that in CKD patients the highest
risk for adverse outcomes with ID is observed when for
the definition of ID a TSAT cutoff level lower than 10%
is used. The use of the TSAT cutoff is largely independ-
ent of the level of serum ferritin. This suggests that em-
phasis should be placed on a low TSAT rather than
ferritin levels in early stage CKD patients. Further re-
search is needed to validate our results in terms of the
effect of iron treatment on outcomes.
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